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Abstract: Symbicort SMART® (Symbicort Maintenance and Reliever Therapy) represents 
a new and unique way of treating patients with moderate-to-severe asthma, ie, those patients 
who require combination treatment with an inhaled corticosteroid and a long-acting inhaled 
β2-agonist. Symbicort SMART enables patients to use only one inhaler, the budesonide-
formoterol combination inhaler, for both maintenance and reliever therapy. The maintenance 
dose is adjustable, but should be a minimum of two doses per day which can be administered 
as two doses once daily or as one dose twice daily. It is important that the temporary reliever 
medication includes not only a bronchodilator but also an antiinﬂ  ammatory drug because 
worsening of asthma includes not only more airway narrowing, but also an increase in airway 
inﬂ  ammation. The Symbicort SMART concept therefore ensures that the patient gets an anti-
inﬂ  ammatory drug at the time of the ﬁ  rst signs of asthma worsening. Clinical results show that 
Symbicort SMART prolongs the time to the ﬁ  rst severe asthma exacerbation, reduces the rate 
of exacerbations, and maintains day-to-day asthma control at a reduced load of corticosteroids 
(inhaled plus systemic) when compared with higher ﬁ  xed maintenance doses of combination 
inhalers. Symbicort SMART consequently offers a more effective and simple approach to asthma 
management for physicians and patients. Symbicort SMART is also easier for the patient as 
only one inhaler is required. The positive results with Symbicort SMART can be explained 
by the early as-needed use on the inhaled corticosteroid component, which puts out the early 
ﬂ  ames of inﬂ  ammation, together with the interaction between the β2-agonist, formoterol, and 
the inhaled corticosteroid, budesonide.
Keywords: asthma control, combination therapy, inhaled corticosteroid, long-acting β2-agonist, 
Symbicort SMART® (Symbicort Maintenance and Reliever Therapy)
Introduction
Patients suffering from asthma dislike having their disease out of control. Fear of 
exacerbations, emergency room visits, and hospitalizations are a reality. The introduc-
tion of effective asthma medications, such as inhaled corticosteroids (ICS), leukotriene 
modiﬁ  ers, and long-acting bronchodilators, have given physicians and patients the 
therapeutic tools for effective treatment but surveys demonstrate that patients’ asthma 
control falls far short of the goals set out in asthma management programmes (Rabe 
et al 2000, 2004; Haughney et al 2004; Hyland and Ståhl 2004; Partridge et al 2006). 
Patients’ perception of asthma control also differs from their actual asthma control 
(Rabe et al 2000). In a recent study of over 3000 patients from 11 countries treated 
with ICS with or without an inhaled long-acting β2-agonist bronchodilator (LABA), 
it was apparent that asthma control is rarely achieved (Partridge et al 2006). Using 
an asthma control questionnaire (ACQ6) (Juniper et al 1999, 2005), 51% of patients 
were found to have uncontrolled asthma, 21% were poorly controlled, and only 28% 
had well controlled asthma. This was despite the fact that 61% of patients were using 
a ﬁ  xed combination of an ICS and a LABA and an additional 9% used the same Therapeutics and Clinical Risk Management 2007:3(2) 350
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medications via separate inhalers. Furthermore, 74% of 
patients reported a daily use of reliever medication and one 
or more exacerbations had occurred during the last year in 
51% of these patients. At the time of deteriorating, asthma, 
patients tended to increase their dose of ICS late and the mean 
increase was less than two-fold. This was despite the fact that 
patients wanted to achieve immediate relief and were willing 
to self-manage their disease. It is thus obvious that the current 
management situation too often results in a major negative 
impact on patients’ health-related quality of life.
The discrepancy between asthma control and available 
treatment strategies may depend upon a variety of different 
factors. For example, poor compliance may result in inad-
equate maintenance therapy, management guidelines may not 
have been implemented, and the degree of disease severity 
may have been misinterpreted. All these factors can lead to 
insufﬁ  cient medication at time of asthma worsening.
Worsening of asthma is not only a gradual change in 
airway calibre but is primarily, and more importantly, an 
increase in underlying airway inﬂ  ammation. In a study of 
patients with stable asthma requiring ICS at daily doses 
≥800 µg of beclomethasone or equivalents, mild exacerba-
tions were induced by reducing the ICS treatment to 200 µg 
of budesonide per day (Jatakanon et al 2000). This study 
demonstrated that an increase in the number of sputum 
eosinophils and an increase in exhaled nitric oxide, which 
both are markers of airway inﬂ  ammation, occurred before 
worsening of symptoms was reported. Therefore, maintaining 
asthma control during a phase of asthma deterioration and 
preventing exacerbations, such as at times of a viral infec-
tion or increased exposure to allergens or irritants, requires 
an increase in antiinﬂ  ammatory medication in addition to 
more frequent use of reliever bronchodilators. 
Treatment approaches
The 1-year FACET (Formoterol and Corticosteroids 
Establishing Therapy) study demonstrated how exacerbations 
can be avoided. Signiﬁ  cant reductions in the rate of severe 
asthma exacerbations were seen by adding formoterol to a 
low (100 µg bid) or a four times higher dose (400 µg bid) 
of the ICS budesonide compared with the budesonide doses 
alone (Pauwels et al 1997). It was also shown that the four 
times higher budesonide dose resulted in signiﬁ  cantly fewer 
severe exacerbations than low dose budesonide. Similarly, in 
patients with mild persistent asthma who were not sufﬁ  ciently 
well controlled on an ICS alone, the addition of formoterol 
to a low dose of budesonide signiﬁ  cantly reduced the rate of 
asthma exacerbations (O’Byrne et al 2001). 
Combination inhalers were developed based on the results 
of the above-mentioned studies with an ICS and a LABA 
administered in separate inhalers. The ﬁ  rst clinical study 
showed at least similar efﬁ  cacy when the same doses were 
administered via one or two inhalers (Zetterström et al 2001). 
Later studies with ICS/LABA combinations administered via 
one or two separate inhalers have shown clear advantages 
for the single inhaler (Angus et al 2005). 
Common clinical practice is to recommend doubling the 
dose of ICS at times of asthma worsening. This is probably 
not the most appropriate recommendation as clinical studies 
have shown that doubling the ICS dose is not enough for 
preventing asthma exacerbations (Garrett et al 1998; FitzGer-
ald et al 2004; Harrison et al 2004). The ICS dose increase 
needs to be higher. Other studies have shown that in many 
patients a temporary increase in ICS dose on top of a lower 
maintenance dose at the time of deterioration is as effective 
in maintaining asthma control and preventing exacerbations 
as a higher maintenance dose (Foresi et al 2000). 
Strategies involving the use of an ICS only as needed 
without maintenance therapy during asthma deterioration 
have been evaluated in patients with mild persistent asthma 
(Boushey et al 2005). Although some patients are well 
controlled on as-needed therapy alone, and no difference in 
exacerbation rates was seen between regular and intermit-
tent treatment with budesonide in the study, this treatment 
approach has been justiﬁ  ably criticized (O’Byrne 2005). It 
appears that patients with mild persistent asthma remain best 
controlled when they use regular maintenance medication 
with an antiinﬂ  ammatory drug (Haahtela et al 1994). This 
was also seen in the study by Boushey and colleagues (2005) 
where regular treatment with budesonide was demonstrated 
to be superior to intermittent medication with regard to 
asthma-free days, lung function, and markers of inﬂ  amma-
tion. However, the daily maintenance dose of the ICS can 
be quite low (Haahtela et al 2006).
The message from all these different treatment strategies 
is clear. In the case of asthma worsening it is not sufﬁ  cient 
to increase the bronchodilator dose: the inhaled antiinﬂ  am-
matory medication must also be appropriately increased. 
Without this, there is a great risk that patients have to be 
treated with systemic corticosteroids for at least 1–2 weeks 
and sometimes for much longer times. With this in mind it 
is of interest to review the published Symbicort SMART lit-
erature, ie, a treatment approach with budesonide-formoterol 
administered both as maintenance and reliever therapy en-
sures that the patient gets an antiinﬂ  ammatory treatment at 
every time of the ﬁ  rst signs of asthma worsening. Therapeutics and Clinical Risk Management 2007:3(2) 351
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Combination of an inhaled 
long-acting β2-agonist and an 
inhaled corticosteroid
Patients with mild persistent asthma, ie, those with regular 
symptoms but a normal airway function, are usually well 
controlled on a medication consisting of an ICS as mainte-
nance therapy and a rapid-acting β2-agonist used as needed. 
Patients not adequately controlled with ICS alone beneﬁ  t 
from the addition of a LABA (NIH GINA 2006). An ICS 
and a LABA can be administered via separate inhalers or 
in a combination product. Two combination products are 
available: budesonide-formoterol (Symbicort®, AstraZeneca 
Ltd, Lund, Sweden), and salmeterol-ﬂ  uticasone (SeretideTM/
AdvairTM, GlaxoSmithKline, Uxbridge, UK). They are both 
effective and safe therapies, but differ in two aspects. Inhaled 
formoterol has a rapid onset of action, similar to that of the 
short- and rapid-acting β2-agonist salbutamol (Seberová 
and Andersson 2000), whereas the onset of bronchodilation 
(Palmqvist et al 1997) and reversal of methacholine-induced 
bronchoconstriction (Politiek et al 1999) with salmeterol are 
signiﬁ  cantly slower. Similarly, both the onset of broncho-
dilation (Palmqvist et al 2001) and the reversal of metha-
choline-induced bronchoconstriction (van der Woude et al 
2004) are signiﬁ  cantly faster with budesonide-formoterol 
compared with salmeterol-ﬂ  uticasone. The systemic activity 
of formoterol is as short-acting as with salbutamol or terbu-
taline (Tötterman et al 1998; Seberová and Andersson 2000; 
Malolepszy et al 2001). Consequently the risk of side effects 
with repeated dosing of formoterol is no different to that with 
repeated administration of salbutamol or terbutaline. Further-
more, it is often forgotten that single doses of budesonide 
exhibit relevant antiinﬂ  ammatory effects. A single dose of 
budesonide has been shown to decrease sputum eosinophil 
levels signiﬁ  cantly (Gibson et al 2001) and the level of ni-
tric oxide in exhaled air was also signiﬁ  cantly reduced six 
hours after a single dose of nebulized budesonide to children 
with acute asthma (Tsai et al 2001). An increase in sputum 
eosinophils and in the amount of nitric oxide in exhaled air 
are predictive for the loss of asthma control (Jakatonon et al 
2000). Already single doses of budesonide-formoterol thus 
favorably affect an early inﬂ  ammation.
Both components of budesonide-formoterol exhibit a 
dose-response (Ellul-Micallef and Johansson 1983; Ringdal 
et al 1998) and very high doses of both have been found 
to be safe and well tolerated (Busse et al 1998; Tötterman 
et al 1998; Malolepszy et al 2001; Boonsawat et al 2003; 
Rubinfeld et al 2006). This allows patients an easy way to 
increase the number of daily doses of both budesonide and 
formoterol without changing inhaler devices in the event of 
worsening asthma. On the other hand, the systemic activity 
of salmeterol is as long-lasting as that of the bronchodilation 
and therefore additional doses cannot be given without caus-
ing more side effects (Bennett and Tattersﬁ  eld 1997; Guhan 
et al 2000). Increasing the dose of salmeterol above 50 µg 
increases tremor and other side effects, but does not improve 
airway function (Ullman and Svedmyr 1988; Palmqvist et al 
1999). Consequently, during asthma worsening patients on 
salmeterol-ﬂ  uticasone must add the ICS via another inhaler 
or change, if possible, from one combination strength of 
salmeterol-ﬂ  uticasone to another. 
Due to the properties of budesonide-formoterol, this 
review will focus on a new smarter way of using this com-
bination in the treatment of patients with moderate-to-severe 
asthma. Budesonide-formoterol is available in two strengths 
for the treatment of asthma: 80/4.5 µg and 160/4.5 µg per 
dose (delivered doses corresponding to 100/6 µg and 200/6 
µg metered doses). A higher strength, 320/9 µg per dose, is 
mainly used for the treatment of chronic obstructive pulmo-
nary disease.
Adjustable maintenance therapy 
with budesonide-formoterol
As described above the clinical pharmacology proﬁ  le of 
budesonide-formoterol allows the daily dose to be adjusted 
in response to disease severity without changing inhaler. 
A series of clinical studies have been presented evaluating 
the clinical value of adjusting the dose of budesonide-
formoterol compared with a ﬁ  xed daily dose (Ställberg et al 
2003; FitzGerald et al 2003; Leuppi et al 2003; Aalbers et al 
2004; Buhl et al 2004; Canonica et al 2004; Ind et al 2004; 
Holt et al 2005). The general principle for these randomized 
comparisons has been that patients with moderate severe 
asthma were ﬁ  rst stabilized on two doses twice daily of 
budesonide-formoterol. Patients randomized to ﬁ  xed dosing 
continued on two doses twice daily while monitoring peak 
ﬂ  ow, recording night-time awakenings, and use of β2-agonists 
to determine when medical checks and treatment with oral 
steroids were required in a situation of severe asthma wors-
ening. Patients randomized to the adjustable dosing arm and 
fulﬁ  lling stability requirements had their daily dose reduced 
to one dose twice daily. In the case of asthma worsening this 
dose was increased to four doses twice daily for 1–2 weeks. 
When stability criteria were again achieved patients reduced 
their dose to one in the morning and one in the evening. In Therapeutics and Clinical Risk Management 2007:3(2) 352
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the majority of the cited studies, the total burden of corti-
costeroids (ICS for maintenance therapy plus oral cortico-
steroids during exacerbations) was found to be signiﬁ  cantly 
reduced compared with treatment with higher ﬁ  xed dosing 
of ICS. However, measures of asthma control, eg, asthma 
symptoms, use of reliever medication, airway function, and 
night-time awakenings due to asthma, were not signiﬁ  cantly 
different between groups randomized to ﬁ  xed or adjustable 
maintenance treatment of budesonide-formoterol. 
The take-home message from this programme is in line 
with the long-time experiences gained with ICS: at the time 
of asthma worsening the steroid dose must be increased in 
order to avoid exacerbations and hospitalizations. This can 
now also be done by temporarily quadrupling the mainte-
nance dose of budesonide-formoterol. The total burden of 
corticosteroids was signiﬁ  cantly lower compared with ﬁ  xed 
dosing of ICS/LABA combination products.
Budesonide-formoterol as both 
maintenance and reliever therapy
Considering the fact that an asthma exacerbation is the com-
bination of an increase in both inﬂ  ammation and broncho-
constriction, it seemed logical to investigate the usefulness 
of budesonide-formoterol as both maintenance and reliever 
therapy. This treatment approach has been coined Symbicort 
SMART® (Symbicort Maintenance and Reliever Therapy) 
(Gibson 2005) and means that patients are taking deﬁ  ned 
maintenance doses of budesonide-formoterol and additional 
doses as needed instead of a short-acting reliever. There are 
currently seven published studies evaluating the effectiveness 
of this treatment approach.
In initial 6- and 12-month Symbicort SMART stud-
ies, two doses of budesonide-formoterol were given once 
daily with additional doses as needed and compared with 
a higher dose of budesonide alone with terbutaline used 
as needed (Scicchitano et al 2004; Rabe, Pizzichini, 
et al 2006). As expected airway function improved when 
a LABA was added, but, more importantly, the risk of 
severe asthma exacerbations was reduced despite the fact 
that patients in the Symbicort SMART treatment arms 
used less steroids. In both studies total asthma symptom 
scores, symptom-free days, as-needed medication-free 
days, and asthma-control days, ie, a night and day with no 
asthma symptoms, no use of reliever medication, and no 
asthma-related night-time awakenings, were statistically 
significantly lower in the Symbicort SMART groups. In 
one of the studies (Rabe, Pizzichini, et al 2006) night-
time awakenings did not reach the level of statistical 
significance (p = 0.065).
The Symbicort SMART approach was more rigorously 
tested in a 12-month study in patients with moderate-to-
severe asthma (n = 2760) where Symbicort SMART (twice 
daily maintenance treatment with budesonide-formoterol 
80/4.5 µg plus additional doses as needed; patients aged 4–11 
years old inhaled the medication once daily in the evening) 
was compared with a four times higher dose of budesonide 
alone with terbutaline as needed. Patients in a third treatment 
arm used a ﬁ  xed dose of budesonide-formoterol with terbu-
taline as needed (O’Byrne et al 2005). Symbicort SMART 
therapy improved airway function signiﬁ  cantly more than the 
two other treatments. It prolonged the time to the ﬁ  rst severe 
asthma exacerbation (p < 0.001) resulting in a 45%–47% 
lower exacerbation risk versus budesonide-formoterol in 
ﬁ  xed dosing (hazard ratio [HR] 0.55, 95% conﬁ  dence interval 
[CI] 0.44, 0.67) or four times higher budesonide dose (HR 
0.53, 95% CI 0.43, 0.65) (Figure 1). These results in favor 
of Symbicort SMART were achieved despite lower steroid 
use in that group. The adult patients used mean doses of 
budesonide of 240 µg, 160 µg, and 640 µg in the Symbicort 
SMART, budesonide-formoterol ﬁ  xed dosing, and higher 
budesonide dose groups, respectively, and in addition oral 
steroids on 1255, 2918, and 2577 days, respectively, during 
the entire study period. In children (n = 341) similar results 
were seen (Bisgaard et al 2006), where the budesonide doses 
were 126 µg, 80 µg, and 320 µg per day and the number of 
days with oral steroids were 32, 230, and 141, respectively. 
Compared with budesonide-formoterol ﬁ  xed dosing plus ter-
butaline as needed, the Symbicort SMART treatment resulted 
in statistically signiﬁ  cantly lower use of reliever medication, 
night-time asthma symptoms and awakenings, but not in less 
daytime symptoms, symptom-free days, reliever-free days, 
or asthma control days.
To reﬂ  ect clinical practice, another 12-month study 
compared Symbicort SMART with salmeterol-ﬂ  uticasone in 
adjustable doses plus salbutamol as needed. Adjustment of 
salmeterol-ﬂ  uticasone was performed by changing inhalers 
based on actual asthma control as assessed by the physician 
(Vogelmeier et al 2005). The Symbicort SMART concept, as 
per the above studies, resulted in a 25% lower risk of having 
a ﬁ  rst asthma exacerbation (p = 0.01) (Figure 2). The cumula-
tive risk of having a severe exacerbation was 22% lower in 
the Symbicort SMART group (p < 0.05) with 0.24 events per 
patient per year in the Symbicort SMART group compared 
with 0.31 events in the salmeterol-ﬂ  uticasone group. The 
difference in risk of having a severe exacerbation was true Therapeutics and Clinical Risk Management 2007:3(2) 353
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Figure 1 Time to ﬁ  rst severe asthma exacerbation. The Symbicort SMART approach resulted in a 45% reduction compared with budesonide-formoterol maintenance 
therapy with terbutaline as needed, and in a 47% reduction compared with the four times higher dose of budesonide maintenance dose and terbutaline used as needed. 
American Thoracic Society copyright © 2005. Data reproduced with permission from O’Byrne PM, Bisgaard H, Godard PP, et al. 2005. Budesonide-formoterol combination 
therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 171:129–36. Ofﬁ  cial journal of the American Thoracic Society.
Abbreviations: BUD, budesonide; FORM, formoterol; TERB, terbutaline.
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Figure 2 The cumulative rate of severe exacerbations in a study comparing budesonide-formoterol as maintenance and reliever therapy (Symbicort SMART®) compared 
with salmeterol-ﬂ  uticasone in adjustable dosing and salbutamol used as needed. Symbicort SMART reduced the exacerbation rate by 22% (p < 0.01). Copyright © 2005. 
Reproduced with permission from Vogelmeier C, D’Urzo A, Pauwels R, et al. 2005. Budesonide-formoterol maintenance and reliever therapy: an effective asthma treatment 
option? Eur Respir J, 26:819–28.
Abbreviations: BUD/FORM, budesonide-formoterol; SAL/FP, salmeterol-ﬂ  uticasone.Therapeutics and Clinical Risk Management 2007:3(2) 354
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for all types of exacerbations based on unscheduled visits 
initiated by the patients, hospitalizations, and emergency 
room treatments as well as courses of oral steroids. The 
difference was statistically signiﬁ  cant even when unsched-
uled visits as a cause for exacerbations were excluded. The 
overall mean use of ICS was very similar in the two groups: 
budesonide 562 µg as maintenance dose and additional 91 µg 
per day as needed (total daily dose 653 µg) compared with 
583 µg per day of ﬂ  uticasone. Oral steroids had to be given 
for 1980 days in the Symbicort SMART group compared 
with 2978 days in the salmeterol-ﬂ  uticasone group. Thus a 
clear oral steroid sparing effect was seen in the Symbicort 
SMART study group. Asthma control was evaluated using 
the asthma control questionnaire, ACQ5 (Juniper et al 1999). 
No statistically signiﬁ  cant difference was found between the 
treatment groups.
An open-label study evaluated whether a one dose once-
daily maintenance treatment with Symbicort could be used 
with sustained efﬁ  cacy when additional doses were allowed 
to be taken as needed. Patients with moderate-to-severe 
asthma (n = 491) were randomized to 6 months’ treatment 
with Symbicort SMART 160/4.5 µg once or twice daily 
with additional doses as needed, or to two doses twice daily 
of 160/4.5 µg plus formoterol 4.5 µg as needed (Lundborg 
et al 2005). Thus the patients received one, two, or four 
regular doses per day of budesonide-formoterol. The primary 
variables of efﬁ  cacy were the changes in a modiﬁ  ed ACQ5 
(Juniper et al 1999) and morning peak expiratory ﬂ  ow (PEF). 
No differences between the groups were found in ACQ5 
scores. The exacerbation rates were also similar in the three 
groups, but the study was not powered for detection of differ-
ences in exacerbation rates. Morning PEF was higher in the 
group receiving the high maintenance dose of budesonide-
formoterol compared with the once and twice daily Sym-
bicort SMART groups (differences 13 L/min and 9 L/min, 
respectively; p < 0.002). No difference was seen in asthma 
control days between the twice daily Symbicort SMART 
group and the twice higher budesonide-formoterol ﬁ  xed 
dose group. However, the once daily Symbicort SMART 
group showed a signiﬁ  cant decrease in asthma control days 
compared with the two other groups. Compared with higher 
ﬁ  xed-dose budesonide-formoterol plus formoterol the use 
of budesonide-formoterol was 30%–40% lower in the Sym-
bicort SMART groups. Treatment costs were signiﬁ  cantly 
lower in the Symbicort SMART groups compared with the 
higher ﬁ  xed dose group of budesonide-formoterol.
As one single maintenance dose of Symbicort SMART 
per day resulted in a decrease in asthma control days, such 
a low maintenance treatment should not be recommended 
for patients with moderate persistent asthma. Loss of asthma 
control was also demonstrated in a study comparing salme-
terol-ﬂ  uticasone with an adjustable maintenance dose of 
budesonide-formoterol forcing 82% of patients in the latter 
group to titrate their maintenance dose down from four to 
one inhalation per day (FitzGerald et al 2005). Such a low 
maintenance dose is not in agreement with treatment recom-
mendations for patients with moderate severe asthma (NIH 
GINA 2004). However, in contrast to the study by FitzGerald 
and colleagues (2005), loss of exacerbation control was not 
seen with only one dose of Symbicort SMART. This may 
indicate that the Symbicort SMART approach, when pushed 
to a very low dose, as in the one dose once-daily arm in the 
study by Lundborg and colleagues (2005), allows patients to 
respond immediately to any breakthrough symptoms with an 
effective reliever therapy, thus reducing any danger of exac-
erbations compared with adjustable maintenance regimens 
that rely on detecting a deterioration in control over several 
days before increasing maintenance therapy.
To investigate the importance of the ICS component 
given as needed medication within the Symbicort SMART 
concept a 12-month, three-arm, double-blind, randomized 
study was performed (Rabe, Atienza, et al 2006). All patients 
(n = 3394) received identical twice-daily maintenance doses 
of budesonide-formoterol 160/4.5 µg, but the reliever medi-
cation consisted of terbutaline, formoterol, or budesonide-
formoterol. The time to the ﬁ  rst severe asthma exacerbation 
was longer with as-needed budesonide-formoterol versus for-
moterol (p = 0.005) and longer with formoterol versus terbu-
taline (p = 0.005) (Figure 3). The rate of severe exacerbations 
was 19, 29, and 37 per 100 patients per year with budesonide-
formoterol, formoterol, and terbutaline, respectively, as 
as-needed medication. The ratios of budesonide-formoterol 
versus formoterol was 0.67 (p < 0.0001), budesonide-for-
moterol versus terbutaline 0.52 (p < 0.0001), and formoterol 
versus terbutaline 0.78 (p = 0.00012). Thus the results show 
a signiﬁ  cant beneﬁ  t of adding budesonide to the as-needed 
medication compared with both formoterol and a traditional 
short-acting β2-agonist. 
A recent 6-month study compared Symbicort SMART 
(160/4.5 µg twice daily plus as needed) with the highest, 
ﬁ  xed maintenance dose of budesonide-formoterol (320/9 µg 
twice daily, but with terbutaline used as needed), and with an 
equally high ﬁ  xed dose of salmeterol-ﬂ  uticasone (25/125 µg 
two doses twice daily, and with terbutaline as needed) (Kuna 
et al 2006). A total of 3335 patients aged 12 years or older 
were included. Indicators of asthma control, lung function, Therapeutics and Clinical Risk Management 2007:3(2) 355
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symptoms, and night-time awakenings improved similarly in 
all three groups. Symbicort SMART prolonged the time to 
the ﬁ  rst severe asthma exacerbation compared with the higher 
ﬁ  xed doses of budesonide-formoterol or salmeterol-ﬂ  uticasone 
and was associated with 28% and 39% fewer exacerbations, 
respectively (p < 0.01 for both). The mean exacerbation rates 
were 12, 16, and 19 per 100 patients during the 6-month study 
period in the Symbicort SMART, higher dose budesonide-
formoterol, and salmeterol-ﬂ  uticasone groups, respectively. 
Patients in the Symbicort SMART group used more than 25% 
less ICS than patients in the ﬁ  xed dose groups. 
Safety and tolerability 
of budesonide-formoterol 
The safety and tolerability of the monocomponents of the 
combination inhaler, budesonide and formoterol, have been 
well established during their long-term use. Budesonide 
for inhalation is approved in daily doses up to 1600 µg per 
day. A temporary increase in dose above this level may be 
reﬂ  ected in a temporary suppression of the hypothalamic-
pituitary-adrenal (HPA) axis but without long-term deleteri-
ous effects. It should also be remembered that the alternative 
to using a higher dose of budesonide in the event of asthma 
worsening usually consists of administration of systemic 
corticosteroids, which, from a safety point of view, is a less 
desirable alternative. 
Similarly, inhaled formoterol can be given safely in very high 
doses to patients with acute airway obstruction (Malolepszy et al 
2001; Boonsawat et al 2003; Rubinfeld et al 2006). In one study 
in patients with acute severe asthma, patients received 90 µg 
formoterol or 10 mg terbutaline via Turbuhaler® (AstraZeneca, 
Lund, Sweden) over 180 minutes. The bronchodilatatory capacity 
was similar between formoterol and terbutaline, but formoterol 
had signiﬁ  cantly less effect on pulse rate and serum potassium 
levels (Malolepszy et al 2001). Compared with inhaled salbu-
tamol, formoterol appears to have an improved ratio between 
effects on forced expiratory volume in one second (FEV1) and 
systemic activity measured as decrease in serum potassium 
(Rosenborg et al 2000, 2002).
The combination product (budesonide-formoterol) has 
been found to be safe and well tolerated during long-term 
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Figure 3 Time to the ﬁ  rst severe asthma exacerbation. All patients used similar doses of budesonide-formoterol, as maintenance therapy. The as-needed medication was 
budesonide-formoterol (Symbicort SMART), formoterol or terbutaline. The risk of having a severe exacerbation was reduced by 27% with Symbicort SMART compared 
with formoterol and by 45% compared with terbutaline as as-needed medication. Copyright © 2006. Reproduced with permission from Rabe KF, Atienza T, Magyar P, et al. 
2006. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet, 368:744–53.
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use (Rosenhall et al 2002, 2003) and in high doses (Ankerst 
et al 2003).
How does the budesonide-
formoterol combination work 
so well?
The precise molecular mechanisms for the interaction 
between budesonide and formoterol are still not fully un-
derstood. From a simple point of view, it can be seen that 
budesonide inﬂ  uences the chronic asthmatic inﬂ  ammation 
by affecting eosinophils and by reducing the number of sur-
face mast cells in the airways thereby reducing the amount 
of released bronchoconstrictive mediators. Formoterol, on 
the other hand, inﬂ  uences processes not affected by steroids: 
stabilization of mast cell membranes, relaxation of smooth 
muscle cells, inhibition of capillary plasma leak, and sensory 
nerve activation. These combined effects of budesonide-
formoterol are thus complementary and additive (Barnes 
2002, 2007). 
Formoterol increases the translocation of glucocorticoid 
receptors from the cytoplasm into the cell nucleus where 
the steroid exerts its antiinﬂ  ammatory effects (Usmani et al 
2005). The presence of LABA also inﬂ  uences the recycling 
of glucocorticoid receptors by prolonging their stay in the 
nucleus and thereby prolonging steroid antiinﬂ  ammatory 
efﬁ  cacy (Haque et al 2006). Furthermore, formoterol also 
inhibits the release of interleukin (IL)-8 from epithelial cells 
thus affecting the neutrophils, which are present in patients 
with more severe asthma (Maneechotesuwan et al 2005). 
Finally, the interaction between antigen-presenting cells 
and effector cells in the asthmatic inﬂ  ammatory process is 
mediated via GATA-3, a transcription factor that regulates 
the synthesis of Th2 cytokines. GATA-3 is strongly inhibited 
by corticosteroids (Maneechotesuwan et al 2002). 
These mechanisms show that there is a useful molecular 
interaction between budesonide and formoterol, which can 
be either additive or synergistic. Clinically the additive 
effects are obvious. The synergy has been well demonstrated 
in vitro, but not adequately in vivo. These interactions have 
been described in further detail elsewhere (Barnes 2002, 
2007; Miller-Larsson and Selroos 2006). A schematic picture 
of the interaction is shown in Figure 4.
It is known that signs of increased airway inﬂ  ammation 
precede an increase in symptoms and airway obstruction dur-
ing asthma worsening (Jatakonon et al 2000). An important 
clinical component of the Symbicort SMART approach is 
therefore the immediate increase in ICS dose and dosing 
frequency that happens when budesonide-formoterol is used 
also as needed. This was well demonstrated in the study by 
Rabe, Atienza, et al  (2006). At the same time, the rapid-
acting formoterol component counteracts any increase in 
airway smooth muscle contraction. 
Patient perspectives
From the INSPIRE study (Partridge et al 2006), involving 
3047 patients from 11 European countries, it was clear that a 
high proportion of patients (89%) had experienced episodes 
of asthma worsening during the preceding year despite 
being prescribed effective medications. The patients were 
selected for the study by physicians and they were all using 
ICS with or without LABA (approximately one third used an 
ICS alone). Also, patients deﬁ  ned as having well-controlled 
asthma by the ACQ6 (Juniper et al 1999, 2005) were found 
to have had a signiﬁ  cant number of asthma deteriorations in 
the previous year. An encouraging ﬁ  nding was that patients 
were able to detect the periods of worsening early and were 
willing and interested in altering their medication themselves 
to obtain control of their asthma. Patients wanted a treat-
ment that gives immediate relief from symptoms but were 
concerned about taking too much medication when they felt 
well. This could be interpreted as a preference for varying 
therapy according to the individual’s actual need but also for 
reducing the dose of maintenance therapy to the lowest neces-
sary dose that provides effective asthma control. In this study 
there was a large number of patients who self-managed their 
medication as advocated in asthma management guidelines 
(NIH GINA 2006) and wanted to be taught to adjust their 
medication without having to see a physician. 
Surveys also show that patients with asthma prefer simple 
treatment regimens, preferring treatments with as few drugs 
or inhalers as possible (Hyland and Ståhl 2004). When asked 
about ICS, many patients expressed concern about this class 
of drugs and wanted to use the lowest possible dose.
In a recent study using the discrete choice modelling 
technique it was evident that patients would like to be treated 
in a way that avoids hospitalizations and emergency room 
visits. Everyone appreciates a regimen resulting in as few 
symptoms as possible (Haughney et al 2006).
Based on this knowledge, it appears that the Symbicort 
SMART approach could be suitable for many patients with 
moderate-to-severe asthma, thereby fulﬁ  lling their wishes of 
a simple therapy within the framework of a simple and clear 
self-management programme.
Of course, there may be patients who from a medical point 
of view are less suitable for the Symbicort SMART concept. Therapeutics and Clinical Risk Management 2007:3(2) 357
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These include, for example, habitual users of bronchodila-
tors and poor perceivers of asthma symptoms. It is therefore 
important that patients are well informed about the maximum 
number of additional doses of budesonide-formoterol that can 
be taken on single days and over a number of consecutive 
days. There may also be patients who simply do not want to 
adjust their medication based on a self-management plan.
Conclusions
ICS and LABA have complementary effects, and patients 
with asthma not adequately controlled with ICS alone beneﬁ  t 
from the addition of a LABA (NIH GINA 2006). ICS exhibit 
a rapid suppression on airway inﬂ  ammation. Formoterol, the 
LABA in the budesonide-formoterol combination product 
(Symbicort), relaxes airway smooth muscles but also inhibits 
release of mast cell mediators and has inhibitory effects on 
plasma exudation and neutrophilic inﬂ  ammation. ICS and 
LABA can be administered via two separate inhalers but 
using a combination inhaler appears more convenient and 
may improve compliance. Using a low dose of budesonide-
formoterol during periods of good asthma control, and 
temporarily quadrupling the dose for one to two weeks 
when symptoms have developed and a decrease in airway 
function can be recognized, has been found to prevent the 
rate and severity of asthma exacerbations but at a lower total 
corticosteroid dose over time.
Formoterol also has a fast onset of action and can there-
fore be used as rescue therapy in asthma. Markers of inﬂ  am-
mation, such as nitric oxide in exhaled air and number of 
eosinophils in sputum, increase at times of asthma worsening, 
and an increase in ICS dose is therefore also required. In ad-
dition to maintenance treatment the budesonide-formoterol 
combination product has therefore also been evaluated as 
rescue therapy. This treatment approach, Symbicort SMART, 
has been found useful in patients with asthma not adequately 
controlled on ICS alone. Symbicort SMART has not been 
Figure 4 Interaction between budesonide and the long-acting β2-agonists (LABA) formoterol. Budesonide has antiinﬂ  ammatory effects but also increases the numbers of 
β2-receptors, whereas formoterol, as well as inducing direct bronchodilation, acts on glucocorticoid receptors (GR) to increase the antiinﬂ  ammatory effects of budesonide 
and increases the translocation of budesonide into the cell nucleus. Copyright © 2002. Modiﬁ  ed with permission from Barnes PJ. 2002. Scientiﬁ  c rationale for inhaled combi-
nation therapy with long-acting β2-agonists and corticosteroids. Eur Respir J, 19:182–91.
Abbreviations: GRE, glucocorticoid response element. Therapeutics and Clinical Risk Management 2007:3(2) 358
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investigated in controlled studies in comparison with ad-
justable maintenance therapy. Compared with much higher 
ﬁ  xed doses of combination products, the rate and severity 
of exacerbations have been signiﬁ  cantly reduced, and with 
lower total doses of corticosteroids over time while maintain-
ing the same good asthma control.
When comparing adjustable maintenance dosing of 
budesonide-formoterol with Symbicort SMART, from 
the patients’ perspective it seems obvious that they prefer 
effective treatment at the ﬁ  rst signs of asthma worsening 
and do not like to wait until a level of predeﬁ  ned symp-
toms and decrease in airway function have developed. The 
study with three identical Symbicort SMART arms, but 
with different rescue treatments, terbutalin, formoterol, or 
budesonide-formoterol (Rabe, Atienza, et al 2006), clearly 
showed the advantage of using a rescue therapy containing 
an ICS. Therefore, for the vast majority of patients who 
require combination treatment with an ICS and a LABA the 
Symbicort SMART approach appears clinically useful and 
advantageous. Thus Symbicort SMART is also a smart way 
to manage asthma from the patients’ perspective.
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